Sintx Technologies, Inc. (SINT) Stock

Sintx Technologies, Inc. (SINT) is a Healthcare stock trading at $1.49 (as of 2026-08-20), with a market capitalization of $9.93M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sintx Technologies, Inc. (formerly Amedica Corporation) develops and commercializes medical devices and related advanced materials made with silicon nitride. It provides solid and porous silicon nitride, silicon nitrite powder, and silicon nitride coatings, along with composite materials and polyetherketoneketone for biomedical, industrial, and antipathogenic applications, primarily in the United States.

Understand Sintx Technologies, Inc.: how it makes money

Sintx Technologies develops and commercializes medical device and materials based on silicon nitride, and it makes money by selling silicon nitride related products (including solid and porous silicon nitride, powders, coatings, and composite materials) for biomedical, industrial, and antipathogenic applications, primarily in the United States.

The companys profitability depends on whether its silicon nitride research and product development can be successfully commercialized into repeated customer purchases of its medical device materials and related products.

Business quality (Weak): Gross margin is positive (37.9%), but the latest reported operating margin is deeply negative (-843.9%), so investors would need clear evidence that commercialization is scaling faster than operating costs.

Bull case

  • Broad silicon nitride product set for multiple use cases: It offers solid and porous silicon nitride, silicon nitrite powder, silicon nitride coating products, silicon nitride composite materials, and polyetherketoneketone for biomedical, industrial, and antipathogenic applications.
  • Some gross profitability in the latest quarter: For the period ended 2026-03-31, gross margin was 37.9%, indicating product-level economics that are not purely loss-making at the gross level.

Bear case

  • Very large operating loss in the latest quarter: For the period ended 2026-03-31, operating margin was -843.9%, which suggests operating expenses are far outpacing operating revenue.
  • Commercialization risk is central to the model: Because the business focuses on research, development, and commercialization, the key downside is slower customer adoption or slower scaling of product sales than required to cover operating costs.
Valuation — source: SEC EDGAR (first-party)
Price$1.49
Market Cap$9.93M
Price / Book2.06
Price / Sales6.99
FCF Yield-168.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.02M
Net Margin-1018.1%
Revenue Growth (YoY)-64.7%
EPS Growth (YoY)-58.6%
FCF Growth (YoY)-6.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-45.83 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVeracity Capital LLC ($191900.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOEric K. Olson
Employees20
CountryUS
IPO Date2014-02-13

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • NeuroOne Medical Technologies Corporation (NMTC)
  • Adagio Medical Holdings, Inc. (ADGM)
  • SeaStar Medical Holding Corporation (ICU)
  • Intelligent Bio Solutions Inc. (INBS)
  • Co-Diagnostics, Inc. (CODX)
  • enVVeno Medical Corporation (NVNO)
  • Picard Medical, Inc. (PMI)
  • Autonomix Medical, Inc. Common Stock (AMIX)
SINT earnings history · SINT institutional & insider holders · SINT KPIs & operating metrics · SINT financials · SINT investor presentations & press releases · SINT SEC filings · SINT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.